Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 9c
Tweet
Share
E-mailGet Alerts ITCI Hot Sheet
Join SI Premium – FREE
Intra-Cellular Therapies (NASDAQ: ITCI) reported Q3 EPS of ($0.53), $0.09 better than the analyst estimate of ($0.62).
For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Solstice acquiring Element Solutions in $14.5B cash and stock deal
- Radoff-Jumana Group calls for Genesco CEO to lose board chair role
- Vontier completes sale of Teletrac Navman for $220 million
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
The Children's Investment Fund (TCI), EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
